Information Provided By:
Fly News Breaks for November 26, 2019
ACAD
Nov 26, 2019 | 07:51 EDT
Canaccord analyst Sumant Kulkarni said he would use any weakness in Acadia as a chance to initiate or add to positions. The analyst noted the company's release of positive Phase 2 ADVANCE results for Nuplazid in the negative symptoms of schizophrenia. He views the results as encouraging. Kulkarni reiterated his Buy rating on Acadia shares.
News For ACAD From the Last 2 Days
There are no results for your query ACAD